Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy
Authors:
- A. AvilésAAA. Avilés
- N. NeriNNN. Neri
- M. J. NamboMNM. J. Nambo
Open Access
- 4 November 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (2) , 286-288
Abstract
Background: The use of anthracyclines in patients with cancer has been associated with the presence, even when standard doses were employed, of cardiac toxicity, most frequently after 5 years of therapy.Treatment of cancer during pregnancy remains a dilemma because cytotoxic therapy has been associated with the presence of severe side-effects. The outcome of children that received antracyclines during pregnancy, including during the first trimester, remain unknown because long-term follow-up is not available. Patients and methods: Eighty-one children whose mothers (29 acute leukemia, 33 malignant lymphoma and 19 Hodgkin's disease) were treated with cytotoxic drugs, including anthracyclines, during pregnancy were evaluated to detect cardiac toxicity, including clinical evaluation and echocardiogram [all parameters were evaluated, but fraction shortening (FS) was taking as the best parameter to evaluate cardiac toxicity in children] every 5 years after birth until 29 years of age. Results: Children with actual age of 9.3–29.5 years (mean 17.1) did not show any clinical date of cardiac disfunction, in all cases echocardiogram was normal and FS did not showed any abnormality during the follow-up. Conclusions: The use of anthracyclines did not show any clinical or echocardiogram evidence of late cardiac toxicity. We hope that the present report increases the number of reports of the long-term follow-up of children who received cytotoxic drugs, in order to define the best treatment in this special patient setting.Keywords
This publication has 19 references indexed in Scilit:
- Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study GroupJournal of Clinical Oncology, 2004
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in AdultsJournal of Clinical Oncology, 2004
- Use of chemotherapy during human pregnancyThe Lancet Oncology, 2004
- Cardiotoxicity of cytotoxic drugsCancer Treatment Reviews, 2004
- Anthracyclines during pregnancy: embryo–fetal outcome in 160 patientsAnnals of Oncology, 2004
- Cancer in pregnancyAnnals of Oncology, 2003
- Hematological Malignancies and Pregnancy: A Final Report of 84 Children Who Received Chemotherapy In UteroClinical Lymphoma, 2001
- Late Lethal Events in Patients with Diffuse Large B Cell Lymphoma: a Review of 714 Patients Treated in a Single CentreLeukemia & Lymphoma, 2001
- Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas.Journal of Clinical Oncology, 1998